GT201600086A - Pirrolo[12-f][1,2,4]triazinas útiles para tratar infecciones por el virus sincitial respiratorio - Google Patents

Pirrolo[12-f][1,2,4]triazinas útiles para tratar infecciones por el virus sincitial respiratorio

Info

Publication number
GT201600086A
GT201600086A GT201600086A GT201600086A GT201600086A GT 201600086 A GT201600086 A GT 201600086A GT 201600086 A GT201600086 A GT 201600086A GT 201600086 A GT201600086 A GT 201600086A GT 201600086 A GT201600086 A GT 201600086A
Authority
GT
Guatemala
Prior art keywords
pirrolo
triazins
useful
treat infections
respiratory synctial
Prior art date
Application number
GT201600086A
Other languages
English (en)
Spanish (es)
Inventor
Michael Oneil Hanrahan Clarke
Edgard Doerffler
Richard L Mackman
Dustin Siegel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201600086(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of GT201600086A publication Critical patent/GT201600086A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GT201600086A 2013-11-11 2016-05-11 Pirrolo[12-f][1,2,4]triazinas útiles para tratar infecciones por el virus sincitial respiratorio GT201600086A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361902544P 2013-11-11 2013-11-11

Publications (1)

Publication Number Publication Date
GT201600086A true GT201600086A (es) 2018-01-17

Family

ID=52003049

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201600086A GT201600086A (es) 2013-11-11 2016-05-11 Pirrolo[12-f][1,2,4]triazinas útiles para tratar infecciones por el virus sincitial respiratorio

Country Status (36)

Country Link
US (5) US9388208B2 (OSRAM)
EP (3) EP3505173B1 (OSRAM)
JP (7) JP6234571B2 (OSRAM)
KR (4) KR101864973B1 (OSRAM)
CN (3) CN105899216B (OSRAM)
AP (1) AP2016009186A0 (OSRAM)
AU (5) AU2014346665A1 (OSRAM)
BR (1) BR112016010261B1 (OSRAM)
CA (1) CA2928674C (OSRAM)
CL (1) CL2016001120A1 (OSRAM)
CR (1) CR20160220A (OSRAM)
CU (1) CU20160065A7 (OSRAM)
CY (1) CY1121948T1 (OSRAM)
DK (2) DK3068405T3 (OSRAM)
DO (1) DOP2016000107A (OSRAM)
EA (2) EA029712B1 (OSRAM)
ES (2) ES2926155T3 (OSRAM)
GT (1) GT201600086A (OSRAM)
HR (2) HRP20220920T1 (OSRAM)
HU (2) HUE044960T2 (OSRAM)
IL (1) IL245324B (OSRAM)
LT (2) LT3068405T (OSRAM)
MD (1) MD4596C1 (OSRAM)
MX (2) MX376186B (OSRAM)
MY (2) MY197933A (OSRAM)
NZ (1) NZ719592A (OSRAM)
PE (1) PE20160670A1 (OSRAM)
PH (1) PH12016500867A1 (OSRAM)
PL (2) PL3505173T3 (OSRAM)
PT (2) PT3505173T (OSRAM)
SG (1) SG11201603427XA (OSRAM)
SI (2) SI3068405T1 (OSRAM)
TR (1) TR201910961T4 (OSRAM)
UA (1) UA119050C2 (OSRAM)
WO (1) WO2015069939A1 (OSRAM)
ZA (1) ZA201603123B (OSRAM)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2480559B1 (en) 2009-09-21 2013-07-03 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-cyano-carbanucleoside analogs
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
EA031726B1 (ru) 2014-09-26 2019-02-28 Рибосайенс Ллк 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса
TWI740546B (zh) * 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
CN107427529A (zh) 2014-12-26 2017-12-01 埃莫里大学 N4‑羟基胞苷和衍生物及与其相关的抗病毒用途
PL3349758T3 (pl) 2015-09-16 2022-09-12 Gilead Sciences, Inc. Sposoby leczenia zakażeń wirusami arenaviridae
RU2720811C2 (ru) * 2015-09-23 2020-05-13 Мерк Шарп И Доум Лимитед 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы и их получение
US10745427B2 (en) 2016-03-09 2020-08-18 Janssen Biopharma, Inc. Acyclic antivirals
KR102460968B1 (ko) 2017-03-14 2022-11-01 길리애드 사이언시즈, 인코포레이티드 고양이 코로나바이러스 감염의 치료 방법
JP2020518578A (ja) 2017-05-01 2020-06-25 ギリアード サイエンシーズ, インコーポレイテッド (S)−2−エチルブチル2−(((S)−(((2R,3S,4R,5R)−5−(4−アミノピロロ[2,1−f][1,2,4]トリアジン−7−イル)−5−シアノ−3,4−ジヒドロキシテトラヒドロフラン−2−イル)メトキシ)(フェノキシ)ホスホリル)アミノ)プロパノエートの結晶形態
CA3077489A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
CR20200126A (es) * 2017-09-18 2020-07-11 Janssen Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de estos
CN109748921B (zh) * 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-叔丁氧羰基保护的杂环类化合物、其制备方法及其用于制备c-核苷类似物的方法
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CN108787177B (zh) * 2018-08-07 2024-03-15 中南大学 淤浆法制备黄原酸盐的方法及系统
WO2020232194A1 (en) * 2019-05-14 2020-11-19 The Regents Of The University Of Michigan Methods for glycosylation
CN118766947A (zh) 2020-01-27 2024-10-15 吉利德科学公司 用于治疗SARS CoV-2感染的方法
EP4644394A2 (en) 2020-02-18 2025-11-05 Gilead Sciences, Inc. Antiviral compounds
TWI791193B (zh) 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
TWI874791B (zh) * 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) * 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的一种新合成方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
TWI890963B (zh) 2020-03-12 2025-07-21 美商基利科學股份有限公司 1'-氰基核苷之製備方法
CN115362004A (zh) 2020-04-06 2022-11-18 吉利德科学公司 1’-氰基取代的碳核苷类似物的吸入制剂
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
CN111620903A (zh) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
JP2023531524A (ja) 2020-06-24 2023-07-24 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノヌクレオシド類似体及びその使用
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
CN111793101B (zh) * 2020-07-17 2022-09-30 四川大学 C-核苷化合物的合成方法
CA3185450A1 (en) 2020-08-06 2022-02-10 Istvan Borza Remdesivir intermediates
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ, インコーポレイテッド リン脂質化合物及びその使用
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
TW202344257A (zh) * 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
CN112500417B (zh) * 2020-12-31 2022-01-21 山东诚汇双达药业有限公司 一种4-氨基吡咯并[2,1-f][1,2,4]三嗪的制备方法
KR20230170745A (ko) * 2021-04-16 2023-12-19 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
WO2023023527A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN118119624A (zh) 2021-08-20 2024-05-31 盐野义制药株式会社 具有病毒增殖抑制作用的核苷衍生物及其前药
TW202525810A (zh) 2022-03-02 2025-07-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
PE20250419A1 (es) * 2022-03-03 2025-02-14 Gilead Sciences Inc Compuestos antivirales y metodos de elaboracion y uso de los mismos
US20230382940A1 (en) 2022-03-03 2023-11-30 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
EP4665737A1 (en) 2023-02-16 2025-12-24 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2025049699A1 (en) 2023-08-31 2025-03-06 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250084088A1 (en) 2023-08-31 2025-03-13 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2025072641A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (OSRAM) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
KR100246082B1 (ko) 1991-07-02 2000-04-01 인헤일, 인코오포레이티드 에어로졸화된약제를전달하는방법및장치
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
PT2251015E (pt) * 2000-10-18 2013-04-15 Gilead Pharmasset Llc Nucleosídeos modificados para o tratamento de infeções virais e de proliferação celular anormal
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
WO2003026589A2 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
SI2114980T1 (sl) 2007-01-12 2012-11-30 Biocryst Pharm Inc Protivirusni nukleozidni analogi
JP2011513195A (ja) 2007-05-10 2011-04-28 バイオクライスト ファーマシューティカルズ, インコーポレイテッド ウイルス感染およびがんの処置に使用するためのテトラヒドロフロ[3,4−d]ジオキソラン化合物
EP2019519B1 (en) 2007-07-25 2011-07-06 Nokia Siemens Networks Oy Method for addressing ethernet streams with a structured GPON GEM Port ID
AP3076A (en) * 2008-04-23 2014-12-31 Gilead Sciences Inc Carba-nucleoside analogs for antiviral treatment
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
EA201200525A1 (ru) 2009-09-21 2012-09-28 Гайлид Сайэнсиз, Инк. 2'-фторзамещенные карба-нуклеозидные аналоги для противовирусного лечения
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
EP2480559B1 (en) 2009-09-21 2013-07-03 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-cyano-carbanucleoside analogs
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
EP2596004B1 (en) 2010-07-19 2014-09-10 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之2’-氟取代之碳-核苷類似物
CA2807496C (en) * 2010-09-20 2019-01-22 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
TW201701876A (zh) 2010-12-20 2017-01-16 吉李德科學股份有限公司 治療c型肝炎病毒(hcv)之方法
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
PL2794627T3 (pl) * 2011-12-22 2019-04-30 Alios Biopharma Inc Podstawione nukleozydy, nukleotydy i ich analogi
SI2834258T1 (sl) * 2012-03-13 2017-04-26 Gilead Sciences, Inc. 2'-substituirani karba-nukleozidni analogi za protivirusno zdravljenje
HK1207647A1 (en) 2012-10-08 2016-02-05 Idenix Pharmaceuticals Llc 2'-chloro nucleoside analogs for hcv infection
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
EP3068405B1 (en) 2019-05-01
JP2018021051A (ja) 2018-02-08
AU2017232039C1 (en) 2019-07-25
IL245324B (en) 2018-08-30
HRP20191303T1 (hr) 2019-10-18
EP4122932A1 (en) 2023-01-25
US9701682B2 (en) 2017-07-11
HRP20220920T1 (hr) 2022-10-28
UA119050C2 (uk) 2019-04-25
CN110003215A (zh) 2019-07-12
LT3505173T (lt) 2022-10-10
US10377761B2 (en) 2019-08-13
CN105899216B (zh) 2019-03-05
PE20160670A1 (es) 2016-07-10
CL2016001120A1 (es) 2017-05-05
JP2024041986A (ja) 2024-03-27
EA201690978A1 (ru) 2016-09-30
KR101864973B1 (ko) 2018-06-05
MD4596C1 (ro) 2019-05-31
WO2015069939A1 (en) 2015-05-14
CA2928674A1 (en) 2015-05-14
ES2743619T3 (es) 2020-02-20
PH12016500867A1 (en) 2016-06-20
CN114085243A (zh) 2022-02-25
EA039734B1 (ru) 2022-03-04
US20170008897A1 (en) 2017-01-12
US20190055253A1 (en) 2019-02-21
NZ719592A (en) 2017-12-22
SI3068405T1 (sl) 2019-08-30
CA2928674C (en) 2018-10-02
AU2019204381B2 (en) 2021-04-01
CN114085243B (zh) 2024-04-26
AU2021201554B2 (en) 2023-02-02
AU2019204381A1 (en) 2019-07-11
MX2016006066A (es) 2016-08-12
KR102243724B1 (ko) 2021-04-23
JP2022088661A (ja) 2022-06-14
SG11201603427XA (en) 2016-05-30
JP6234571B2 (ja) 2017-11-22
MY182986A (en) 2021-02-05
SI3505173T1 (sl) 2022-09-30
HUE059683T2 (hu) 2022-12-28
JP2020055855A (ja) 2020-04-09
ZA201603123B (en) 2019-08-28
AU2017232039B2 (en) 2019-03-28
EA029712B1 (ru) 2018-05-31
JP2018070658A (ja) 2018-05-10
KR20210046833A (ko) 2021-04-28
PT3068405T (pt) 2019-08-05
AU2023202506A1 (en) 2023-05-11
LT3068405T (lt) 2019-08-12
US20250236623A1 (en) 2025-07-24
MX376186B (es) 2025-03-07
EP3505173A1 (en) 2019-07-03
JP2017502925A (ja) 2017-01-26
PL3068405T3 (pl) 2019-10-31
AU2023202506B2 (en) 2025-01-23
BR112016010261B1 (pt) 2022-02-08
DK3505173T3 (da) 2022-08-22
CY1121948T1 (el) 2020-10-14
MD4596B1 (ro) 2018-10-31
JP7247155B2 (ja) 2023-03-28
DOP2016000107A (es) 2016-06-15
KR102355881B1 (ko) 2022-01-25
CN110003215B (zh) 2021-12-17
AU2017232039A1 (en) 2017-10-12
EA201792639A1 (ru) 2018-09-28
EP3505173B1 (en) 2022-07-06
MX2020010628A (es) 2020-10-22
AU2014346665A1 (en) 2016-05-19
AU2021201554A1 (en) 2021-04-01
PL3505173T3 (pl) 2022-10-17
CR20160220A (es) 2016-07-22
IL245324A0 (en) 2016-06-30
US20150133395A1 (en) 2015-05-14
US20180016280A1 (en) 2018-01-18
KR20160074011A (ko) 2016-06-27
KR102113705B1 (ko) 2020-05-21
CU20160065A7 (es) 2016-09-30
ES2926155T3 (es) 2022-10-24
JP7054394B2 (ja) 2022-04-13
BR112016010261A2 (OSRAM) 2017-08-08
PT3505173T (pt) 2022-11-18
CN105899216A (zh) 2016-08-24
KR20200057103A (ko) 2020-05-25
JP6393380B2 (ja) 2018-09-19
AP2016009186A0 (en) 2016-04-30
TR201910961T4 (tr) 2019-08-21
MD20160063A2 (ro) 2016-11-30
JP2021046413A (ja) 2021-03-25
HUE044960T2 (hu) 2019-12-30
US10059716B2 (en) 2018-08-28
KR20180059958A (ko) 2018-06-05
MY197933A (en) 2023-07-25
EP3068405A1 (en) 2016-09-21
DK3068405T3 (da) 2019-07-29
US9388208B2 (en) 2016-07-12

Similar Documents

Publication Publication Date Title
GT201600086A (es) Pirrolo[12-f][1,2,4]triazinas útiles para tratar infecciones por el virus sincitial respiratorio
BR112016023558A2 (pt) compostos úteis como imunomoduladores
EA201692219A1 (ru) Способы получения противовирусных соединений
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
MX2017001284A (es) Tieno [3,2-d] pirimidina, furo[3,2-d] pirimidina y pirrolo [3,2-d] pirimidinas utiles para el tratamiento de infecciones por virus sincitial respiratorio.
MX381488B (es) Indoles para su uso en la infección por el virus de la gripe.
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
GT201500247A (es) Imidazopiridazinas sustituidas
NZ728707A (en) 2’-chloro aminopyrimidinone and pyrimidine dione nucleosides
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
DOP2016000278A (es) Nuevos compuestos macrocíclicos
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
UY36938A (es) Nuevos compuestos macrocíclicos modificados
UY36221A (es) Derivados de isoindolinona
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX2015010728A (es) Metodos y composiciones para el tratamiento de leucemia.
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
UY36923A (es) Nuevos compuestos macrocíclicos de sulfondiimina
BR112015000392A2 (pt) novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório
CL2017002304A1 (es) Métodos para tratar enfermedades
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas
AR095353A1 (es) Compuesto
UY35600A (es) "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"
MX2016001858A (es) Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion por el virus sincicial respiratorio.